Abstract
Background: Bone metastasis with advance cancer stage forms approximately 85% of all cases. Breast cancer patients frequently suffer from bone pain, functional impairment due to bone metastasis which impacts negatively on their quality of life. Subjects and Methods: A retrospective study of breast cancer patients who have bone metastasis at diagnosis or developing bone metastasis during 5 years from breast cancer diagnosis (2011-2016) and who received zometa 4 mg monthly in radiotherapy department was included and conducted in 2017. We reviewed 107 female with breast cancer diagnosed by bone scan and/or PET scan as cases of bone metastasis enrolled. Questionnaire was designed to document all variables besides, demographic data which contain (age, histopathology reading invasive ductal carcinoma, invasive lobular carcinoma or others, ER status, PR status, Her2neu status and lymph node status & stage, Onset of metastasis, Menopausal Status & finally No. of metastasis site). Results: We noticed that the highest percentage of patients diagnosed as bone metastasis were 45 years and more, and 86% of them were invasive ductal carcinoma; regarding hormonal status we noticed that ER, PR status was positive in 90.7% and 82.2% of cases respectively, Her2neu receptors were amplified in 26.2% of them, positive lymph nodes were seen positive in 80.4% of cases and 31.8% of them were shown (N3) stage; we noticed that the only risk factor of bone metastasis is PR+ significantly associated with lesions multiplicity (0.049). There is no significant association between ER, PR, Her2neu, lymph nodes and menopausal status and onset of bone metastasis, also age, ER, Her2neu, lymph nodes and menopausal status are not associated significantly with No. of metastatic lesions. Conclusion: PR+ is significantly associated with lesions multiplicity (0.049), which is considered as a risk factor of bone metastasis in our study.
Highlights
Breast cancer is the most common cancer among women
We noticed that the highest percentage of patients diagnosed as bone metastasis were 45 years and more, and 86% of them were invasive ductal carcinoma; regarding hormonal status we noticed that ER, PR status was positive in 90.7% and 82.2% of cases respectively, Her2neu receptors were amplified in 26.2% of them, positive lymph nodes were seen positive in 80.4% of cases and 31.8% of them were shown (N3) stage; we noticed that the only risk factor of bone metastasis is PR+ significantly associated with lesions multiplicity (0.049)
The authors noted that the highest percentage of patients who diagnosed as a bone metastasis cases were 45 years and more, 86% of them were invasive ductal carcinoma, regarding hormonal status we noticed that ER, PR status was positive in 90.7% and 82.2% of cases respectively, Her2neu receptors were amplified in 26.2% of them, Luminal A forms the highest molecular
Summary
Breast cancer has excellent prognosis due to advances in management and treatment, a significant number of patients suffer from complication of bone metastasis It is estimated 70% of women with advanced breast cancer [1]. Bisphosphonates are just auxiliary drugs in bone metastasis, which should not be abused [3] Another treatment of bone metastasis from solid tumor is zometa (bisphosphonates); 4 mg is infused around 15 to 30 minutes every 3 to 4 weeks for patients having metastatic bone lesions with creatinine clearance (CrCl) greater than 60 mL/min which is recommended in conjunction with standard cancer therapy [4]. Hospital that tries to identify the most important factors that may affect the incidence of bone metastasis among Jordanian women suffering from breast cancer. The purposes of this study are: 1) To identify the profile of the breast cancer cases associated with bone metastasis in radiation oncology department during last 5 years.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
